82 related articles for article (PubMed ID: 29805623)
1. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma.
Sánchez AIP; Roces LV; García IZ; López EL; Hernandez MAC; Parejo MIB; Peña-Díaz J
Oncol Lett; 2018 Jun; 15(6):8863-8870. PubMed ID: 29805623
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis.
Zhao Y; Liu W; Zheng L; Goyal S; Awosika J; Wang H; Yang S
J Gastrointest Oncol; 2023 Dec; 14(6):2536-2548. PubMed ID: 38196538
[TBL] [Abstract][Full Text] [Related]
3. High pre-treatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma.
Czauderna C; Schmidtmann I; Koch S; Pilz L; Heinrich S; Otto G; Mittler J; Lang H; Kloeckner R; Düber C; Sprinzl MF; Wörns MA; Galle PR; Marquardt JU; Weinmann A
United European Gastroenterol J; 2020 Nov; 9(3):2050640620972611. PubMed ID: 33226301
[TBL] [Abstract][Full Text] [Related]
4. Erratum to "Association between posttreatment α-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma".
Cancer; 2024 Jan; 130(1):162. PubMed ID: 37924321
[No Abstract] [Full Text] [Related]
5. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
[TBL] [Abstract][Full Text] [Related]
6. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
[TBL] [Abstract][Full Text] [Related]
7. Levels of PIVKA-II and alpha-fetoprotein in unresectable hepatocellular carcinoma compared to healthy controls and predictive values of both markers with radiological responses after loco-regional interventions.
Hamzah N; Kassim NK; Omar J; Abdullah MS; Lee YY
PeerJ; 2023; 11():e15988. PubMed ID: 37780370
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.
Pinto E; Pelizzaro F; Farinati F; Russo FP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374319
[TBL] [Abstract][Full Text] [Related]
9. A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.
Lin CL; Liang KH; Hu CC; Chien CH; Chen LW; Chien RN; Lin YH; Yeh CT
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675198
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma.
Brackenier C; Kinget L; Cappuyns S; Verslype C; Beuselinck B; Dekervel J
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672297
[TBL] [Abstract][Full Text] [Related]
11. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma.
Hsu PY; Liang PC; Chang WT; Lu MY; Wang WH; Chuang SC; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Chuang WL; Huang CF; Huang JF; Yu ML
Am J Cancer Res; 2022; 12(12):5576-5588. PubMed ID: 36628276
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
Zhu AX; Dayyani F; Yen CJ; Ren Z; Bai Y; Meng Z; Pan H; Dillon P; Mhatre SK; Gaillard VE; Hernandez S; Kelley RK; Sangro B
Clin Cancer Res; 2022 Aug; 28(16):3537-3545. PubMed ID: 35435967
[TBL] [Abstract][Full Text] [Related]
13. The future is now: beyond first line systemic therapy in hepatocellular carcinoma.
Nenu I; Breaban I; Pascalau S; Bora CN; Stefanescu H
Transl Cancer Res; 2019 Apr; 8(Suppl 3):S261-S274. PubMed ID: 35117106
[TBL] [Abstract][Full Text] [Related]
14. Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Abulimiti M; Li Z; Wang H; Apiziaji P; Abulimiti Y; Tan Y
J Oncol; 2021; 2021():9943683. PubMed ID: 34899910
[TBL] [Abstract][Full Text] [Related]
15. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
Ando Y; Kawaoka T; Kosaka M; Shirane Y; Johira Y; Miura R; Murakami S; Yano S; Amioka K; Naruto K; Kosaka Y; Uchikawa S; Kodama K; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Okamoto W; Takahashi S; Imamura M; Chayama K; Aikata H
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439111
[TBL] [Abstract][Full Text] [Related]
16. Anterior mediastinal large cell neuroendocrine carcinoma with elevated AFP: A case report and review.
Komisarof J; Qiu H; Velez MJ; Mulford D
Mol Clin Oncol; 2021 Feb; 14(2):34. PubMed ID: 33414915
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma with tumor thrombus extends to the right atrium and portal vein: A case report.
Gomez-Puerto D; Mirallas O; Vidal-González J; Vargas V
World J Hepatol; 2020 Nov; 12(11):1128-1135. PubMed ID: 33312435
[TBL] [Abstract][Full Text] [Related]
18. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.
Kelley RK; Meyer T; Rimassa L; Merle P; Park JW; Yau T; Chan SL; Blanc JF; Tam VC; Tran A; Dadduzio V; Markby DW; Kaldate R; Cheng AL; El-Khoueiry AB; Abou-Alfa GK
Clin Cancer Res; 2020 Sep; 26(18):4795-4804. PubMed ID: 32636319
[TBL] [Abstract][Full Text] [Related]
19. Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Kegasawa T; Sakamori R; Maesaka K; Yamada R; Tahata Y; Urabe A; Kodama T; Hikita H; Imanaka K; Ohkawa K; Hiramatsu N; Oshita M; Yamada Y; Inada M; Yakushijin T; Imai Y; Tatsumi T; Takehara T
Dig Dis Sci; 2021 May; 66(5):1720-1729. PubMed ID: 32556820
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
